Phase 1b:~Pediatric subjects with advanced solid and CNS tumors or recurrent or progressive Low-Grade Glioma with selected FGFR1-3 alterations will follow a standard dose escalation, in 3 dose levels, to determine the pediatric recommended Phase 2 dose (RP2D) and to assess the safety.~Dose escalation decisions will be assessed through three dose level cohorts.~Phase 2:~To evaluate the efficacy and safety in Pediatric and adult subjects with LGG with selected FGFR1-3 alterations (including subjects who received infigratinib at the RP2D).
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib.~The phase 2 study will evaluate efficacy and safety of infigratinib.